Novel Anti-lilrb4 antibodies and uses thereof
Novel antibodies targeting LILRB4 with defined CDR sequences address the need for effective AML treatment by modulating immune response and inhibiting leukemia cell proliferation.
US20250361295A1Pending Publication Date: 2025-11-27ANTENGENE BIOLOGICS LTD
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- US18/872279
- Authority / Receiving Office
- US · United States
- Patent Type
- Applications(United States)
- Current Assignee / Owner
- Priority Date
- 2023-05-24
- Filing Date
- 2023-06-05
- Publication Date
- 2025-11-27
AI Technical Summary
Technical Problem
There is a need for novel anti-LILRB4 antibodies to effectively target leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4) for treating acute myeloid leukemia (AML), as existing therapies are limited.
Method used
Development of antibodies or antigen-binding fragments that specifically bind to LILRB4, comprising specific heavy and light chain complementarity determining regions (CDRs) with defined amino acid sequences, capable of modulating immune response and inhibiting leukemia cell proliferation.
Benefits of technology
The antibodies effectively bind to LILRB4, modulating immune response and inhibiting leukemia cell proliferation, offering potential therapeutic benefits for AML treatment.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure US20250361295A1-D00000_ABST
Abstract
The present disclosure provides anti-LILRB4 antibodies or antigen-binding fragments thereof, pharmaceutical composition comprising the same and the uses thereof.
Need to check novelty before this filing date? Find Prior Art